Global Mycoplasma Testing Market Size Study & Forecast, by Product (Instruments, Kits & Reagents) and Technology (PCR, ELISA, Direct Assay, Microbial Culture) and Regional Forecasts 2022-2032

The Global Mycoplasma Testing Market is estimated to be valued at approximately USD 1.07 billion in 2024 and is projected to expand robustly at a CAGR of 13.58% during the forecast period spanning 2025 to 2035. Mycoplasma testing plays a pivotal role in the pharmaceutical and biotechnology industries, ensuring the safety and purity of biological products by detecting contamination that can adversely affect research outcomes and therapeutic applications. These tests employ sophisticated methodologies ranging from PCR to microbial culture techniques, serving as critical tools in quality control for cell culture, vaccine manufacturing, and biopharmaceutical production. The market’s growth is largely propelled by heightened regulatory scrutiny, increasing R&D investments, and the expanding biopharmaceutical sector’s demand for stringent contamination control protocols.

Escalating incidences of contamination in biologics production, alongside rising awareness regarding the adverse impacts of mycoplasma infections on cell cultures, have accelerated the adoption of advanced testing methods. Technological innovations, such as real-time PCR and ELISA, have enhanced the accuracy and speed of detection, thereby supporting the burgeoning need for rapid and reliable screening. Additionally, the surge in contract research organizations (CROs) and the growing emphasis on vaccine development, especially in the wake of global health emergencies, have further underscored the importance of mycoplasma testing. However, challenges such as high testing costs and the availability of alternative contamination control measures might temper the market’s growth trajectory.

Regionally, North America commands a dominant position in the global Mycoplasma Testing Market, buoyed by its well-established pharmaceutical industry, rigorous regulatory framework, and significant expenditure on biotechnology R&D. The U.S., in particular, serves as a major hub due to its advanced healthcare infrastructure and presence of key market players. Europe follows closely, driven by countries like Germany, the UK, and France, where stringent quality standards and increasing biopharmaceutical manufacturing activities prevail. Meanwhile, the Asia Pacific region is anticipated to witness the fastest growth owing to escalating healthcare investments, expanding biotechnology hubs in China and India, and supportive government initiatives fostering research and innovation. Latin America and the Middle East & Africa, though smaller markets currently, are poised for gradual growth fueled by rising healthcare awareness and infrastructural development.

Major market players included in this report are:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Lonza Group Ltd.
• Qiagen N.V.
• Charles River Laboratories International, Inc.
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• Roche Diagnostics
• Abbott Laboratories
• Greiner Bio-One International GmbH
• Tecan Group Ltd.
• Eurofins Scientific SE
• Danaher Corporation
• Sartorius AG

Global Mycoplasma Testing Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast Period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Instruments
• Kits & Reagents

By Technology:
• PCR
• ELISA
• Direct Assay
• Microbial Culture

By Application:

(Various industry-specific applications to be defined based on available data)

By End-Use:

(Clinical laboratories, pharmaceutical & biotechnology companies, contract research organizations, others)

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe (ROE)

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific (RoAPAC)

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more